1. A clinical trial examining the effect of increased total CRM197 carrier protein dose on the antibody response to Haemophilus influenzae type b CRM197 conjugate vaccine
- Author
-
Vytautas Usonis, Vytautas Bakasenas, Stephen Lockhart, Sherryl Baker, William Gruber, and France Laudat
- Subjects
Male ,Diphtheria Toxoid ,Meningococcal Vaccines ,Diphtheria-Tetanus-acellular Pertussis Vaccines ,medicine.disease_cause ,complex mixtures ,Pneumococcal conjugate vaccine ,Haemophilus influenzae ,Bacterial Proteins ,Conjugate vaccine ,Humans ,Medicine ,Drug Interactions ,Haemophilus Vaccines ,Diphtheria toxin ,integumentary system ,General Veterinary ,General Immunology and Microbiology ,business.industry ,Tetanus ,Diphtheria ,Public Health, Environmental and Occupational Health ,Toxoid ,Infant ,medicine.disease ,Antibodies, Bacterial ,Virology ,Infectious Diseases ,Immunology ,Molecular Medicine ,Female ,business ,medicine.drug ,Conjugate - Abstract
CRM(197) is a carrier protein in certain conjugate vaccines. When multiple conjugate vaccines with the same carrier protein are administered simultaneously, reduced response to vaccines and/or antigens related to the carrier protein may occur. This study examined responses of infants who, in addition to diphtheria toxoid/tetanus toxoid/acellular pertussis vaccine (DTaP) received either diphtheria CRM(197)-based Haemophilus influenzae type b conjugate vaccine (HbOC) or HbOC and a diphtheria CRM(197)-based combination 9-valent pneumococcal conjugate vaccine/meningococcal group C conjugate vaccine. Administration of conjugate vaccines with CRM(197) carrier protein load >50 microg did not reduce response to CRM(197) conjugate vaccines or immunogenicity to immunologically cross-reactive diphtheria toxoid.
- Published
- 2008